Cipla
Market cap ₹1.09 L Cr
- P/E
- 32.49
- Day range
- ₹1,330.00 – ₹1,360.00
- 52-week range
- ₹1,165.70 – ₹1,593.80
- Volume
- 15.48 L
- Open
- ₹1,336.60
- Prev close
- ₹1,338.00
Latest results · Q1 FY27(consolidated)Revenue ₹7,119 Cr+2.3%Profit ₹786 Cr-39.2%Margin 11.0%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
CIPLA in NSE indices and F&O
F&O margin for one lot of CIPLA (425 shares)Research profile
Composite 60 / 100Factor percentiles
Derived metrics
- Earn. yield
- 3.1%
- Graham no.
- ₹655.79
- vs Graham
- -51.6%
- ROE ÷ P/B
- 3.7%
- 12-1 mom.
- -10.8%
- Return / vol
- -0.67
- Magic Formula
- #359
- Piotroski
- 1/6
- FCF yield
- 0.8%
Appears in 9 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 67 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.17 L Cr | 34.52 | 5.02 | 14.8% | 21.0% | 29.0% | 0.06 | +10.5% |
| Divi's LaboratoriesDIVISLAB | ₹2.40 L Cr | 82.12 | 14.18 | 16.2% | 22.0% | 41.0% | 0.00 | +27.8% |
| Torrent PharmaTORNTPHARM | ₹1.73 L Cr | 76.86 | 9.37 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Zydus LifesciencesZYDUSLIFE | ₹1.16 L Cr | 25.86 | 4.20 | 20.1% | 21.0% | 24.0% | 0.46 | +22.0% |
| Apollo HospitalsAPOLLOHOSP | ₹1.13 L Cr | 53.97 | 11.73 | 22.6% | 17.0% | 16.0% | 0.90 | +20.6% |
| Laurus LabsLAURUSLABS | ₹1.11 L Cr | 101.77 | 20.06 | 18.2% | 18.0% | 32.0% | 0.48 | +29.0% |
| CiplaCIPLA | ₹1.09 L Cr | 32.49 | 3.14 | 11.8% | 15.0% | 17.0% | 0.02 | +2.3% |
| Dr. Reddy's LabsDRREDDY | ₹1.09 L Cr | 39.03 | 2.65 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Sector median | ₹24,447 Cr | 41.53 | 5.60 | 15.1% | 17.0% | 25.0% | 0.16 | +20.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 17m agoHeadlines about Cipla from the last two weeks in the financial press. Stories belong to their publishers; Parasram India does not endorse them.
Key metrics
- P/E (TTM)
- 30.2
- EPS (TTM)
- ₹41.70
- Price / Book
- 3.18
- ROE (FY26)
- 11.8%
- ROCE (latest year)
- 15%
- Dividend yield
- 0.97%
Moving averages (NSE)
- 20-day
- ₹1,338.9
- Price above
- 50-day
- ₹1,379
- Price below
- 200-day
- ₹1,369.03
- Price below
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- DII
- Promoter
- FII
- Public
- Government
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,678 | 6,604 | 6,163 | 6,694 | 7,051 | 7,073 | 6,730 | 6,957 | 7,589 | 7,074 | 6,541 | 7,119 |
| Expenses | 4,944 | 4,856 | 4,847 | 4,978 | 5,165 | 5,084 | 5,192 | 5,179 | 5,695 | 5,819 | 5,586 | 5,927 |
| Operating Profit | 1,734 | 1,748 | 1,316 | 1,716 | 1,886 | 1,989 | 1,538 | 1,778 | 1,895 | 1,255 | 955 | 1,192 |
| OPM % | 26% | 26% | 21% | 26% | 27% | 28% | 23% | 26% | 25% | 18% | 15% | 17% |
| Other Income | 176 | -10 | 249 | 160 | 191 | 222 | 289 | 259 | 269 | -70 | 148 | 211 |
| Interest | 26 | 30 | 18 | 18 | 15 | 15 | 14 | 14 | 13 | 14 | 13 | 17 |
| Depreciation | 290 | 233 | 288 | 247 | 272 | 280 | 309 | 253 | 297 | 278 | 383 | 304 |
| Profit before tax | 1,594 | 1,474 | 1,259 | 1,611 | 1,789 | 1,916 | 1,504 | 1,770 | 1,854 | 893 | 707 | 1,082 |
| Tax % | 28% | 28% | 26% | 27% | 27% | 17% | 19% | 27% | 27% | 24% | 22% | 27% |
| Net Profit | 1,155 | 1,068 | 932 | 1,175 | 1,305 | 1,575 | 1,214 | 1,292 | 1,353 | 674 | 543 | 786 |
| EPS in Rs | ₹14.01 | ₹13.08 | ₹11.63 | ₹14.58 | ₹16.13 | ₹19.45 | ₹15.13 | ₹16.06 | ₹16.73 | ₹8.37 | ₹6.87 | ₹9.77 |
From company filings, updated 26 Oct 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+7 days since Mar 2021
+20 days since Mar 2021
+20 days since Mar 2021
+7 days since Mar 2021
+12 days since Mar 2021
Strengths, risks & growth
Incorporated in 1935, Cipla Ltd is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs [1]
Strengths
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 25.7%
Risks
- The company has delivered a poor sales growth of 8.01% over past five years.
- Promoter holding has decreased over last 3 years: -4.26%
Compounded Sales Growth
- 10 Years
- +7%
- 5 Years
- +8%
- 3 Years
- +7%
- TTM
- +2%
Compounded Profit Growth
- 10 Years
- +11%
- 5 Years
- +10%
- 3 Years
- +10%
- TTM
- -34%
Stock Price CAGR
- 10 Years
- +9%
- 5 Years
- +8%
- 3 Years
- +4%
- 1 Year
- -16%
Return on Equity
- 10 Years
- +13%
- 5 Years
- +14%
- 3 Years
- +15%
- Last Year
- +12%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 29.22% | 29.22% | 29.22% | 29.20% | -0.02 pp |
| FII | 23.93% | 22.55% | 20.20% | 20.24% | +0.04 pp |
| DII | 30.45% | 31.71% | 34.35% | 34.61% | +0.26 pp |
| Government | 0.27% | 0.27% | 0.28% | 0.33% | +0.05 pp |
| Public | 16.12% | 16.26% | 15.93% | 15.60% | -0.33 pp |
Filed with NSE for Sept 2026: promoters 29.21%, public 70.79% · XBRL filing
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 20.78% (+0.22 pp)- Promoters29.2%
- Foreign institutions20.3%
- Mutual funds20.8%
- Insurance11.7%
- Other domestic institutions2.5%
- Retail6.7%
- Others8.9%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| HDFC Flexi Cap Fund | 2.50% | 2.47% | -0.33 pp |
| Parag Parikh Flexi Cap Fund | 1.80% | 1.33% | -0.14 pp |
| ICICI Pru Value Fund | 0.76% | 1.35% | -0.00 pp |
| SBI ELSS Tax Saver Fund | 0.63% | 2.13% | -0.06 pp |
| HDFC Focused Fund | 0.63% | 2.40% | -1.33 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.
Risk & trend
From 275 daily sessions to 23 Oct 2026.
Risk
- Volatility (1Y)
- 20.5%
- Downside volatility
- 19.2%
- Worst 5% of days
- 2.2%
- Average of that tail
- 2.9%
- Max drawdown (1Y)
- 28.3%
- Below its peak
- 19.6%
Against the market
- Beta vs Nifty 50
- 0.60
- Correlation
- 0.39
- Relative strength (3M)
- +1.4%
- ATR (14)
- 1.9%
Return
- Return 1M
- -3.3%
- Return 3M
- -3.9%
- Return 6M
- +8.2%
- Return 1Y
- -13.8%
- vs 200-day average
- -2.3%
Momentum
- RSI (14)
- 46.9
- MACD histogram
- 3.17
- Stochastic %K
- 78.0
- ADX (14)
- 22.8
- +DI / −DI
- 12.7 / 20.6
- Money flow index
- 52.6
Participation
- Delivery (20d avg)
- 56.6%
- vs its 60-day baseline
- -0.2 pts
- Volume vs 20-day
- +1.1σ
- Close vs day's VWAP
- +0.9%
- 52-week position
- 31 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 31 Mar 2026.
Piotroski F-Score
1 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — failed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — failed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — failed
- Asset turnover improving — failed
- Free cash flow
- ₹861 Cr
- FCF yield
- 0.8%
- Cash conversion
- 1.02
- Accruals ratio
- -0.002
- Net debt
- -₹404 Cr
- Net debt / equity
- -0.01
- EV / sales
- 3.80
- Capex intensity
- 10.9%
- Revenue CAGR
- -2.8%
- Profit CAGR
- -55.3%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
Renu Jain jointly with Dinesh Jain Immediate relative · Gift | Buy | 15,419 | ₹0 | 1 Oct 2025 |
Anusha Jain jointly with Dinesh Jain Immediate relative · Gift | Sell | 15,419 | ₹0 | 1 Oct 2025 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Corporate actions
- dividend₹13.00
Dividend - Rs 13 Per Share
5 Jun 2026ex-date - dividend₹13.00
Dividend - Rs 13 Per Share/Special Dividend - Rs 3 Per Share
27 Jun 2025ex-date - dividend₹13.00
Dividend - Rs 13 Per Share
2 Aug 2024ex-date - dividend₹8.50
Dividend - Rs 8.50 Per Share
21 Jul 2023ex-date - dividend₹5.00
Dividend - Rs 5 Per Share
8 Aug 2022ex-date - dividend₹5.00
Annual General Meeting/Dividend - Rs 5 Per Share
9 Aug 2021ex-date - otherNot available — not reported in this filing
Annual General Meeting
11 Aug 2020ex-date - dividend₹3.00
Interim Dividend - Rs 3 Per Share Special Dividend - Re 1 Per Share
19 Mar 2020ex-date - dividend₹3.00
Annual General Meeting/Dividend - Rs 3 Per Share
31 Jul 2019ex-date - dividend₹3.00
Annual General Meeting/Dividend- Rs 3 Per Share
13 Aug 2018ex-date - dividend₹2.00
Annual General Meeting/Dividend - Rs 2/- Per Share
26 Jul 2017ex-date - dividend₹2.00
Annual General Meeting/Dividend Rs 2/- Per Share
12 Sept 2016ex-date - dividend₹2.00
Annual General Meeting/Dividend - Rs 2/- Per Share
11 Aug 2015ex-date - dividend₹2.00
Annual General Meeting/Dividend Rs 2/- Per Equity Share
6 Aug 2014ex-date - dividend₹2.00
Annual General Meeting/Dividend Rs 2/- Per Equity Share
6 Aug 2013ex-date - dividend₹2.00
Annual General Meeting And Dividend - Rs.2/- Per Share
1 Aug 2012ex-date - dividend₹2.00
Annual General Meeting And Dividend Rs.2/- Per Share
9 Aug 2011ex-date - dividendNot available — not reported in this filing
Special Interim Dividend Re.0.80 Per Share
3 Sept 2010ex-date - dividend₹2.00
Annual General Meeting And Dividend Rs.2/- Per Share
23 Jul 2010ex-date - otherNot available — not reported in this filing
Agm/Div-Rs.2/- Per Share
10 Aug 2009ex-date
Company announcements
Please find enclosed disclosure.
Certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed intimation for Earnings Conference Call.
Cipla Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve the unaudited standalone and consolidated ....
In terms of Regulation 30 of SEBI (LODR) Regulations, 2015, we hereby notify that the Operations and Administrative Committee of the Company on 24th September, 2026 has allotted 12,168 ....
Please find enclosed disclosure relating to the Change in SMP.
Please find enclosed disclosure on ESG Rating.
Please find enclosed press release titled 'Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda (Pembrolizumab) in the US'
Please find enclosed disclosure
Please find attached newspaper publication regarding opening of special window for re-lodgement of transfer and dematerialisation of physical shares
Please find enclosed press release titled "Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102)"
Please find enclosed disclosure.
Please find enclosed disclosure.
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herein mention the schedule of Analyst / ....
In terms of regulation 30 of SEBI (LODR) Regulations, 2015, we hereby notify that the Operations and Admisnistrative Committee of the Company on 26th August, 2026 has allotted 5,281 fully ....
Filed with BSE (scrip 500087); the last 45 days. Documents open at bseindia.com.
SEBI filings & orders
From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.
Regulatory orders
- Order
Summary Settlement Order in respect of Dr. Ranjana Pathak in the matter of Cipla Limited.
23 Sept 2019Read on SEBI
Documents
Annual reports
Earnings calls
- Jul 2026TranscriptSlidesRecording
- May 2026TranscriptSlidesRecording
- Jan 2026TranscriptSlidesRecording
- Nov 2025TranscriptSlidesRecording
- Jul 2025TranscriptSlidesRecording
- May 2025TranscriptSlides
Credit ratings
- Rating update · 10 Sep from care
- Rating update · 19 Dec 2025 from fitch
- Rating update · 26 Aug 2025 from care
- Rating update · 20 Dec 2024 from fitch
- Rating update · 8 Oct 2024 from care
- Rating update · 11 Jan 2024 from fitch
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 24 Jul 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Cipla: common questions
Answered from the figures on this page.
